Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 30,418Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Saphris

PharmaCompass

01

Brand Name : Saphris

arrow
2024 ACI Convention
Not Confirmed

Asenapine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 155

2016 Revenue in Millions : 167

Growth (%) : -7

Abbvie CB

02

Brand Name : Saphris

arrow
2024 ACI Convention
Not Confirmed

Asenapine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 140

2017 Revenue in Millions : 155

Growth (%) : -10%

Abbvie CB

03

Brand Name : Saphris

arrow
2024 ACI Convention
Not Confirmed

Asenapine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2016 Revenue in Millions : 167

2015 Revenue in Millions : 187

Growth (%) : -11

Abbvie CB

04

Brand Name : Saphris

arrow
2024 ACI Convention
Not Confirmed

Asenapine

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 135

2018 Revenue in Millions : 140

Growth (%) : -3

Abbvie CB

05

Brand Name : Saphris

Asenapine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Saphris

arrow
2024 ACI Convention
Not Confirmed

Asenapine

Main Therapeutic Indication : Neuroscience/Mental Health

Currency : USD

2014 Revenue in Millions :

2013 Revenue in Millions :

Growth (%) :

blank